Teva continues its transformation, hiring Christine Fox to take over US business

Teva Pharmaceuticals' new CEO Richard Francis has continued his transformation of the Israeli company, bringing on Christine Fox as the new head of its U.S. commercial business, replacing 15-year Teva veteran Sven Dethlefs, who departs Nov. 17.

Fox arrives from Novartis, where she has been the global president of gene therapies for nearly two years. Before that, Fox spent six years at Amgen, holding three different vice president posts, including heading up sales and, later, the cardiometabolic, bone and nephrology unit.